Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radspherin in Colorectal Peritoneal Carcinomatosis
NCT03732781Phase 2Completed
- Sponsor
- Oncoinvent AS
- Start
- May 2020
- Primary completion
- May 2025
- Modality
- Nanoparticles
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Radspherin in peritoneal carcinomatosis (PC) and colorectal carcinoma (CRC), sponsored by Oncoinvent AS. Primary endpoints: Dose Limiting Toxicities at 18 months, Maximum Tolerated Dose at 21 days and 1 more. Started May 2020; status: completed.
02
Drugs
Radspherin
03
Conditions
peritoneal carcinomatosis (PC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT03732781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732781.